$4.47
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Immuneering Corporation Announces Grants of Inducement Awards
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering Names Andrew Gengos as CFO
Overview
52-week range
$1.66
$10
33% of range
Avg surprise (last 3)
+9.2%
Avg reaction (last 2)
+0.6%
100% positive
Latest IV / EM
132%
EM ±30.2% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.21 | $-0.30 | +30.0% | +50.0% | +0.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.38 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.40 | $-0.40 | 0.0% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.42 | $-0.41 | -2.4% | — | +0.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.49 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.47 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.49 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.43 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.43 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.25 | -$0.40 | +37.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-15M | $-15M | $-15M | — | $-15M | $-15M |
| Net income | $-13M | — | $-15M | $-14M | $-15M | — | $-15M | $-14M |
| EPS (diluted) | $-0.21 | — | $-0.38 | $-0.40 | $-0.42 | — | $-0.49 | $-0.47 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $47M | $129M | $228M | $26M | $36M | $36M | $45M | $60M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $161M | $176M | $229M | $28M | $38M | $40M | $55M | $64M |
| Total assets | $215M | $232M | $241M | $40M | $51M | $53M | $69M | $77M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $8M | $14M | $13M | $11M | $9M | $11M | $11M | $11M |
| Total equity | $207M | $218M | $228M | $29M | $42M | $41M | $58M | $66M |